CAR-T Cell Therapy proves to be an important invention in the domain of cancer treatment. However, its applications are still confined to treating only a few liquid tumors that are in the relapsed and refractory stage. Domains such as optimizing autologous CAR-Ts for liquid tumors, expanding the number of CAR-T providing healthcare settings, innovating the production of next-generation CAR T-cell therapies, and reducing the innovation cycle time to improve efficacy in solid tumors, still lack R&D.
In CAR T-cell therapy, T-cells from the blood of the patient are enhanced by adding a gene for a chimeric antigen receptor. This helps to recognize specific cancer cell antigens. The enhanced CAR T-cells are then administered to the patient.
The biotechnology and life science sectors display continuous growth in R&D when thinking about the usage of chimeric antigen receptors for cancer treatment. Several countries are conducting substantial studies for the validation of CAR T-Cell therapy’s mechanism of action, efficiency and effectiveness, and compliance in patients with lymphoma and leukemia.
Several key companies have been trying to develop therapies for the CAR T-cell therapy market. These include companies like Novartis Pharmaceuticals, Takeda, REGENERON, Johnson & Johnson, Sangamo Therapeutics Inc, Bellicum Pharmaceuticals Inc, Juventas Cell Therapy, Novartis International AG, Helix BioPharma, Sensei Biotherapeutics, Amgen Inc, Celgene Corporation, Pfizer Inc, Bluebird Bio, Gilead Sciences Inc, and many others.
Approved CAR T-Cell therapies include:
- Breyanzi (lisocabtagene maraleucel) – by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Abecma (idecabtagene vicleucel) – by Celgene Corporation, a Bristol-Myers Squibb Company
- Tecartus (brexucabtagene autoleucel) – by Kite Pharma Inc.
- Yescarta (axicabtagene ciloleucel) – by Kite Pharma Inc.
- Kymriah (tisagenlecleucel) – by Novartis Pharmaceuticals Corporation
Recent developments in CAR T-Cell therapy market:
- May 2019: Japanese government panel approves the sale of Kymriah in Japan via Novartis.
- Nov 2018: Celgene acquires Juno Therapeutics ; Nov 2019: Bristol-Myers Squibb acquires Celgene.
- Dec 2017: Gilead Science acquires Cell Design Labs Inc.
- Gilead Science acquires Kite Pharma Inc.
The immuno-oncology field receives millions of dollars of investments. CAR T-cell therapy, which has the potential to directly rewire the immune system and make it capable of fighting cancer, has created big expectations. With more than 500 clinical trials under study, many more pharmaceutical companies can try developing different CAR T-cell therapies for the treatment of cancer in the future.
Source: CAR-T Cell Therapy Market – Emerging Therapies and Key Companies. By Delveinsight.
DaveKev's Life Science 01 